Cerevel Therapeutics Holdings is a clinical-stage biopharmaceutical company. Co.'s programs: Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype; Darigabat, which is a PAM that selectively targets the alpha-2/3/5 subunits of the GABAA receptor; Tavapadon, which is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of early- and late-stage Parkinson's disease; and CVL-871, which is a selective dopamine D1/D5 receptor partial agonist specifically designed to achieve a level of partial agonism. The CERE average annual return since 2020 is shown above.
The Average Annual Return on the CERE average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CERE average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CERE average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|